{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:58Z","timestamp":1787009638137,"version":"build-2736575974"},"reference-count":97,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["GNT1111136"],"award-info":[{"award-number":["GNT1111136"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Obesity and adverse metabolic outcomes in patients with severe mental illness are clinically significant but potentially preventable. Importantly, the evidence for switching to antipsychotics to reduce cardiometabolic burden is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>PubMED, Embase, PsycINFO, and Cochrane were searched from inception to March 8, 2020. Articles reporting weight and metabolic changes after antipsychotic switching vs staying on the previous antipsychotic were meta-analyzed both across and within group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 61 identified studies, 59 were meta-analyzed (40% rated high quality). In the switch-vs-stay pairwise meta-analyses, only aripiprazole significantly reduced weight (\u22125.52 kg, 95% CI \u221210.63, \u22120.42, P = .03), while olanzapine significantly increased weight (2.46 kg, 95% CI 0.34, 4.57, P = .02). Switching to aripiprazole also significantly improved fasting glucose (\u22123.99 mg\/dl, 95% CI \u22127.34, \u22120.64, P = .02) and triglycerides (\u221231.03 mg\/dl, 95% CI \u221248.73, \u221213.34, P = .0001). Dropout and psychosis ratings did not differ between switch and stay groups for aripiprazole and olanzapine. In before-to-after switch meta-analyses, aripiprazole (\u22121.96 kg, 95% CI \u22123.07, \u22120.85, P &amp;lt; .001) and ziprasidone (\u22122.22 kg, 95% CI \u22123.84, \u22120.60, P = .007) were associated with weight loss, whereas olanzapine (2.71 kg, 95% CI 1.87, 3.55, P &amp;lt; .001), and clozapine (2.80 kg, 95% CI 0.26, 5.34, P = .03) were associated with weight gain. No significant weight or other cardiometabolic changes were observed when switching to amisulpride, paliperidone\/risperidone, quetiapine, or lurasidone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching antipsychotics to agents with lower weight gain potential, notably to aripiprazole and ziprasidone, can improve weight profile and other cardiometabolic outcomes. When choosing switch agents, both the weight gain potential of the pre- and post-switch antipsychotic must be considered. Antipsychotic switching in psychiatrically stable patients must be weighed against the risk of psychiatric worsening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbaa191","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T07:12:59Z","timestamp":1608621179000},"page":"948-958","source":"Crossref","is-referenced-by-count":72,"title":["Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"first","affiliation":[{"name":"Metro South Addiction and Mental Health Service, Brisbane, Australia"},{"name":"School of Medicine, University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Metro South Addiction and Mental Health Service, Brisbane, Australia"},{"name":"School of Medicine, University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Winckel","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Queensland, Brisbane, Australia"},{"name":"Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Hollingworth","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-2924","authenticated-orcid":false,"given":"Steve","family":"Kisely","sequence":"additional","affiliation":[{"name":"Metro South Addiction and Mental Health Service, Brisbane, Australia"},{"name":"School of Medicine, University of Queensland, Brisbane, Australia"},{"name":"Department of Psychiatry, Community Health and Epidemiology, Dalhousie University, Halifax, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Firth","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY"},{"name":"Department of Psychiatry, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, NY"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Marteene","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Redlands Hospital, Cleveland, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"issue":"1","key":"2021070901543876200_CIT0001","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"issue":"6","key":"2021070901543876200_CIT0002","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur Psychiatry"},{"issue":"3","key":"2021070901543876200_CIT0003","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13679-015-0169-4","article-title":"Overweight and obesity: prevalence, consequences, and causes of a growing public health problem","volume":"4","author":"Williams","year":"2015","journal-title":"Curr Obes Rep"},{"key":"2021070901543876200_CIT0004","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev-med-050913-022228","article-title":"Obesity and cancer: local and systemic mechanisms","volume":"66","author":"Iyengar","year":"2015","journal-title":"Annu Rev Med"},{"key":"2021070901543876200_CIT0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpsychires.2018.04.019","article-title":"Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis","volume":"102","author":"Oakley","year":"2018","journal-title":"J Psychiatr Res"},{"key":"2021070901543876200_CIT0006","doi-asserted-by":"crossref","first-page":"f2539","DOI":"10.1136\/bmj.f2539","article-title":"The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers","volume":"346","author":"Lawrence","year":"2013","journal-title":"BMJ"},{"issue":"10046","key":"2021070901543876200_CIT0007","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Collaboration","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2021070901543876200_CIT0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2012.113905","article-title":"Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis","volume":"309","author":"Flegal","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"2021070901543876200_CIT0009","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2021070901543876200_CIT0010","doi-asserted-by":"crossref","first-page":"573479","DOI":"10.3389\/fendo.2020.573479","article-title":"Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness","volume":"11","author":"Mazereel","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2021070901543876200_CIT0011","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/oby.2007.133","article-title":"Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder","volume":"16","author":"Kolotkin","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"2021070901543876200_CIT0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res"},{"key":"2021070901543876200_CIT0013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"1","key":"2021070901543876200_CIT0014","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials","volume":"18","author":"Vancampfort","year":"2019","journal-title":"World Psychiatry"},{"issue":"3","key":"2021070901543876200_CIT0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/wps.20773","article-title":"A meta-review of \u201clifestyle psychiatry\u201d: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders","volume":"19","author":"Firth","year":"2020","journal-title":"World Psychiatry"},{"issue":"6","key":"2021070901543876200_CIT0016","doi-asserted-by":"crossref","first-page":"e0156208","DOI":"10.1371\/journal.pone.0156208","article-title":"Metformin for clozapine associated obesity: a systematic review and meta-analysis","volume":"11","author":"Siskind","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"2021070901543876200_CIT0017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2021070901543876200_CIT0018","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000502293","article-title":"Lifestyle interventions for weight management in people with serious mental illness: a systematic review with meta-analysis, trial sequential analysis, and meta-regression analysis exploring the mediators and moderators of treatment effects","volume":"88","author":"Speyer","year":"2019","journal-title":"Psychother Psychosom"},{"issue":"12","key":"2021070901543876200_CIT0019","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14740338.2019.1674809","article-title":"Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia","volume":"18","author":"Marteene","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"2021070901543876200_CIT0020","article-title":"Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems","author":"Mukundan","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2021070901543876200_CIT0021","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2021070901543876200_CIT0022","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"9","key":"2021070901543876200_CIT0023","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"7109","key":"2021070901543876200_CIT0024","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"2021070901543876200_CIT0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/wps.20714","article-title":"Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial","volume":"19","author":"Correll","year":"2020","journal-title":"World Psychiatry"},{"issue":"5","key":"2021070901543876200_CIT0026","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.11m07074","article-title":"Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial","volume":"73","author":"Covell","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2021070901543876200_CIT0027","first-page":"34","article-title":"The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia","volume":"2014","author":"Danilov","year":"2014","journal-title":"Controlled Clinical Trial"},{"issue":"4","key":"2021070901543876200_CIT0028","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/TCRM.S3153","article-title":"Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder","volume":"4","author":"Deberdt","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"2021070901543876200_CIT0029","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1185\/030079908X297385","article-title":"Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia","volume":"24","author":"Faries","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2021070901543876200_CIT0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4088\/JCP.v64n0203","article-title":"Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia","volume":"64","author":"Godleski","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"2021070901543876200_CIT0031","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"2021070901543876200_CIT0032","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","article-title":"Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine","volume":"31","author":"Kinon","year":"2006","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"2021070901543876200_CIT0033","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am J Psychiatry"},{"key":"2021070901543876200_CIT0034","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/NDT.S80925","article-title":"\u201cEffects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a randomized, open-label study\u201d: corrigendum","volume":"11","author":"Wani","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"4","key":"2021070901543876200_CIT0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/YIC.0b013e328080ca44","article-title":"Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia","volume":"22","author":"Baptista","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"2021070901543876200_CIT0036","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1177\/0269881111430748","article-title":"Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study","volume":"26","author":"Chen","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"6","key":"2021070901543876200_CIT0037","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-2007-992140","article-title":"Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia","volume":"40","author":"De Marinis","year":"2007","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"2021070901543876200_CIT0038","first-page":"243","article-title":"Safety and efficacy of olanzapine in patients with severe haloperidol side effects","volume":"12","author":"Dossenbach","year":"2000","journal-title":"Research Article"},{"issue":"3","key":"2021070901543876200_CIT0039","first-page":"115","article-title":"Switch of therapy to aripiprazole in swiss practices (TRACE: Treatment with Aripiprazole based on Case Experience)","volume":"158","author":"Dubuis","year":"2007","journal-title":"Article"},{"issue":"2","key":"2021070901543876200_CIT0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2190\/PM.45.2.c","article-title":"Switching to ziprasidone in the clinical practice setting: an open-label study","volume":"45","author":"Fraile","year":"2013","journal-title":"Int J Psychiat Med"},{"issue":"2","key":"2021070901543876200_CIT0041","first-page":"548","article-title":"Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial: corrigendum","volume":"36","author":"Gaebel","year":"2011","journal-title":"Randomized Controlled Trial"},{"issue":"2","key":"2021070901543876200_CIT0042","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3371\/CSRP.5.2.3","article-title":"Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole","volume":"5","author":"Ganguli","year":"2011","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"1","key":"2021070901543876200_CIT0043","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2003.09.016","article-title":"Weight decline in patients switching from olanzapine to quetiapine","volume":"70","author":"Gupta","year":"2004","journal-title":"Schizophr Res"},{"issue":"1","key":"2021070901543876200_CIT0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12991-014-0039-6","article-title":"Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study","volume":"14","author":"Hashimoto","year":"2015","journal-title":"Ann Gen Psychiatry"},{"issue":"6","key":"2021070901543876200_CIT0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.jcp.0000239791.91330.48","article-title":"The relationship between prolactin levels and glucose homeostasis in antipsychotic-treated schizophrenic patients","volume":"26","author":"Howes","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"2021070901543876200_CIT0046","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1744-859X-9-35","article-title":"A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting","volume":"9","author":"Hsieh","year":"2010","journal-title":"Ann Gen Psychiatry"},{"issue":"6","key":"2021070901543876200_CIT0047","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/JCP.0000000000000426","article-title":"Fast versus slow strategy of switching patients with schizophrenia to aripiprazole from other Antipsychotics","volume":"35","author":"Hwang","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2021070901543876200_CIT0048","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/01.pra.0000396061.05269.c8","article-title":"Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder","volume":"17","author":"Karayal","year":"2011","journal-title":"J Psychiatr Pract"},{"issue":"3-4","key":"2021070901543876200_CIT0049","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/B:ACLI.0000008171.90644.f8","article-title":"Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia","volume":"15","author":"Kelly","year":"2003","journal-title":"Ann Clin Psychiatry"},{"issue":"10","key":"2021070901543876200_CIT0050","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1185\/03007995.2013.816277","article-title":"Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents","volume":"29","author":"Kim","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2021070901543876200_CIT0051","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0b013e3180a9076c","article-title":"Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study","volume":"27","author":"Kim","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2021070901543876200_CIT0052","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/YIC.0b013e328356acad","article-title":"Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial","volume":"27","author":"Kim","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"2021070901543876200_CIT0053","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0b013e3181d52b85","article-title":"Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia","volume":"33","author":"Kim","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"2021070901543876200_CIT0054","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","article-title":"Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia","volume":"32","author":"Kim","year":"2009","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"2021070901543876200_CIT0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.9758\/cpn.2016.14.4.371","article-title":"Amisulpride switching in schizophrenic patients who showed suboptimal effect and\/or tolerability to current antipsychotics in a naturalistic setting: an explorative study","volume":"14","author":"Kim","year":"2016","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"4","key":"2021070901543876200_CIT0056","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4306\/pi.2014.11.4.459","article-title":"The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder","volume":"11","author":"Ko","year":"2014","journal-title":"Psychiatry Investig"},{"issue":"4","key":"2021070901543876200_CIT0057","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1819.2009.01977.x","article-title":"Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders","volume":"63","author":"Lai","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"2021070901543876200_CIT0058","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hup.723","article-title":"Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone","volume":"20","author":"Larmo","year":"2005","journal-title":"Hum Psychopharmacol"},{"issue":"7","key":"2021070901543876200_CIT0059","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4088\/JCP.v63n0706","article-title":"Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific","volume":"63","author":"Lee","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"2021070901543876200_CIT0060","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40261-013-0120-y","article-title":"The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study","volume":"33","author":"Lee","year":"2013","journal-title":"Clin Drug Investig"},{"issue":"16","key":"2021070901543876200_CIT0061","first-page":"2136","article-title":"A twenty-four-week, open-label study on Ziprasidones efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder","volume":"17","author":"Li","year":"2013","journal-title":"Comparative Study"},{"issue":"6","key":"2021070901543876200_CIT0062","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/JCP.0b013e3181bf613e","article-title":"Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics","volume":"29","author":"Lin","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2021070901543876200_CIT0063","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3371\/CSRP.5.4.2","article-title":"Ziprasidone\u2019s effect on metabolic markers in patients with diabetes and chronic schizophrenia","volume":"5","author":"Lindenmayer","year":"2012","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"1","key":"2021070901543876200_CIT0064","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pnpbp.2006.06.006","article-title":"Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics","volume":"31","author":"Lu","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1-3","key":"2021070901543876200_CIT0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.psychres.2007.06.015","article-title":"Quetiapine for elderly non-responsive schizophrenia patients","volume":"157","author":"Mazeh","year":"2008","journal-title":"Psychiatry Res"},{"issue":"2","key":"2021070901543876200_CIT0066","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","article-title":"Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study","volume":"74","author":"McEvoy","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"2021070901543876200_CIT0067","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.euroneuro.2009.04.002","article-title":"Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study","volume":"19","author":"Pae","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"2021070901543876200_CIT0068","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1185\/030079906X112561","article-title":"Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial","volume":"22","author":"Potvin","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2021070901543876200_CIT0069","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.pnpbp.2007.06.008","article-title":"Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial","volume":"31","author":"Ratner","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"2021070901543876200_CIT0070","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0278-5846(02)00222-1","article-title":"Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study","volume":"26","author":"Rodr\u00edguez-P\u00e9rez","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"2021070901543876200_CIT0071","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11599080-000000000-00000","article-title":"Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable","volume":"32","author":"Rosa","year":"2012","journal-title":"Clin Drug Investig"},{"issue":"4","key":"2021070901543876200_CIT0072","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YIC.0b013e3282f94905","article-title":"Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone","volume":"23","author":"Rossi","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"2021070901543876200_CIT0073","first-page":"184","article-title":"Efficacy and safety of long-acting risperidone on early onset schizophrenia in adolescent patients","volume":"4","author":"Ruan","year":"2010","journal-title":"Afr J Pharm Pharmaco"},{"issue":"7","key":"2021070901543876200_CIT0074","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":"Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison","volume":"63","author":"Shaw","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"2021070901543876200_CIT0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4088\/JCP.12m08084","article-title":"Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study","volume":"74","author":"Stahl","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"2021070901543876200_CIT0076","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.psychres.2015.12.030","article-title":"Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: a prospective observational study","volume":"236","author":"Takaesu","year":"2016","journal-title":"Psychiatry Res"},{"issue":"10","key":"2021070901543876200_CIT0077","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4088\/JCP.v67n1013","article-title":"Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial","volume":"67","author":"Takahashi","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2021070901543876200_CIT0078","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JCP.0b013e3181842586","article-title":"A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering","volume":"28","author":"Takeuchi","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2021070901543876200_CIT0079","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","article-title":"Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study","volume":"64","author":"Takeuchi","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"issue":"7","key":"2021070901543876200_CIT0080","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jpsychires.2006.03.008","article-title":"Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study","volume":"40","author":"Wang","year":"2006","journal-title":"J Psychiatr Res"},{"issue":"1-3","key":"2021070901543876200_CIT0081","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2013.11.042","article-title":"A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia","volume":"153","author":"Weiden","year":"2014","journal-title":"Schizophr Res"},{"issue":"5","key":"2021070901543876200_CIT0082","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.npp.1301482","article-title":"Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone","volume":"33","author":"Weiden","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"2021070901543876200_CIT0083","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0000000000000136","article-title":"Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder","volume":"31","author":"Woo","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"2021070901543876200_CIT0084","doi-asserted-by":"crossref","first-page":"423","DOI":"10.9758\/cpn.2019.17.3.423","article-title":"Switching antipsychotics to blonanserin in patients with schizophrenia: an open-label, prospective, multicenter study","volume":"17","author":"Woo","year":"2019","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"3","key":"2021070901543876200_CIT0085","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2021070901543876200_CIT0086","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"10202","key":"2021070901543876200_CIT0087","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"2021070901543876200_CIT0088","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2021070901543876200_CIT0089","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-859X-12-32","article-title":"Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review","volume":"12","author":"Olivares","year":"2013","journal-title":"Ann Gen Psychiatry"},{"issue":"4","key":"2021070901543876200_CIT0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: a systematic review and meta-analysis","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"2021070901543876200_CIT0091","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"4","key":"2021070901543876200_CIT0092","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2021070901543876200_CIT0093","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull"},{"issue":"2","key":"2021070901543876200_CIT0094","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 Years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr Bull"},{"issue":"4","key":"2021070901543876200_CIT0095","doi-asserted-by":"crossref","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS One"},{"issue":"16","key":"2021070901543876200_CIT0096","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"2021070901543876200_CIT0097","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/47\/4\/948\/38886647\/sbaa191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/47\/4\/948\/38886647\/sbaa191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T04:01:10Z","timestamp":1625803270000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/47\/4\/948\/6129512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":97,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,6]]},"published-print":{"date-parts":[[2021,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbaa191","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,2,6]]}}}